312 related articles for article (PubMed ID: 35710046)
41. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders.
Beach TG; White CL; Hladik CL; Sabbagh MN; Connor DJ; Shill HA; Sue LI; Sasse J; Bachalakuri J; Henry-Watson J; Akiyama H; Adler CH;
Acta Neuropathol; 2009 Feb; 117(2):169-74. PubMed ID: 18982334
[TBL] [Abstract][Full Text] [Related]
42. Propagated α-synucleinopathy recapitulates REM sleep behaviour disorder followed by parkinsonian phenotypes in mice.
Shen Y; Yu WB; Shen B; Dong H; Zhao J; Tang YL; Fan Y; Yang YF; Sun YM; Luo SS; Chen C; Liu FT; Wu JJ; Xiao BG; Yu H; Koprich JB; Huang ZL; Wang J
Brain; 2020 Dec; 143(11):3374-3392. PubMed ID: 33170925
[TBL] [Abstract][Full Text] [Related]
43. Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction.
Gentzel RC; Toolan D; Jinn S; Schachter JB; Ma L; Kahle PJ; Smith SM; Marcus JN
Neurobiol Aging; 2021 Oct; 106():12-25. PubMed ID: 34225000
[TBL] [Abstract][Full Text] [Related]
44. α-Synucleinopathy phenotypes.
McCann H; Stevens CH; Cartwright H; Halliday GM
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S62-7. PubMed ID: 24262191
[TBL] [Abstract][Full Text] [Related]
45. Unique seeding profiles and prion-like propagation of synucleinopathies are highly dependent on the host in human α-synuclein transgenic mice.
Lloyd GM; Sorrentino ZA; Quintin S; Gorion KM; Bell BM; Paterno G; Long B; Prokop S; Giasson BI
Acta Neuropathol; 2022 Jun; 143(6):663-685. PubMed ID: 35488930
[TBL] [Abstract][Full Text] [Related]
46. Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology.
Teil M; Dovero S; Bourdenx M; Arotcarena ML; Camus S; Porras G; Thiolat ML; Trigo-Damas I; Perier C; Estrada C; Garcia-Carrillo N; Morari M; Meissner WG; Herrero MT; Vila M; Obeso JA; Bezard E; Dehay B
Brain; 2022 Apr; 145(3):1001-1017. PubMed ID: 35285474
[TBL] [Abstract][Full Text] [Related]
47. Differential insular cortex subregional vulnerability to α-synuclein pathology in Parkinson's disease and dementia with Lewy bodies.
Fathy YY; Jonker AJ; Oudejans E; de Jong FJJ; van Dam AW; Rozemuller AJM; van de Berg WDJ
Neuropathol Appl Neurobiol; 2019 Apr; 45(3):262-277. PubMed ID: 29797340
[TBL] [Abstract][Full Text] [Related]
48. Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term.
Rey NL; George S; Steiner JA; Madaj Z; Luk KC; Trojanowski JQ; Lee VM; Brundin P
Acta Neuropathol; 2018 Jan; 135(1):65-83. PubMed ID: 29209768
[TBL] [Abstract][Full Text] [Related]
49. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
Spillantini MG; Goedert M
Ann N Y Acad Sci; 2000; 920():16-27. PubMed ID: 11193145
[TBL] [Abstract][Full Text] [Related]
50. Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLB.
Yan R; Zhang J; Park HJ; Park ES; Oh S; Zheng H; Junn E; Voronkov M; Stock JB; Mouradian MM
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E12053-E12062. PubMed ID: 30509990
[TBL] [Abstract][Full Text] [Related]
51. The role of Cdk5-mediated apurinic/apyrimidinic endonuclease 1 phosphorylation in neuronal death.
Huang E; Qu D; Zhang Y; Venderova K; Haque ME; Rousseaux MW; Slack RS; Woulfe JM; Park DS
Nat Cell Biol; 2010 Jun; 12(6):563-71. PubMed ID: 20473298
[TBL] [Abstract][Full Text] [Related]
52. α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease.
Sorrentino ZA; Giasson BI; Chakrabarty P
Acta Neuropathol; 2019 Jul; 138(1):1-21. PubMed ID: 30798354
[TBL] [Abstract][Full Text] [Related]
53. Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery.
Arotcarena ML; Teil M; Dehay B
Cells; 2019 Jun; 8(6):. PubMed ID: 31181865
[TBL] [Abstract][Full Text] [Related]
54. Lewy body pathology involves the olfactory cells in Parkinson's disease and related disorders.
Saito Y; Shioya A; Sano T; Sumikura H; Murata M; Murayama S
Mov Disord; 2016 Jan; 31(1):135-8. PubMed ID: 26748832
[TBL] [Abstract][Full Text] [Related]
55. Inhibitors of nuclease and redox activity of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1).
Laev SS; Salakhutdinov NF; Lavrik OI
Bioorg Med Chem; 2017 May; 25(9):2531-2544. PubMed ID: 28161249
[TBL] [Abstract][Full Text] [Related]
56. G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.
Volpicelli-Daley LA; Abdelmotilib H; Liu Z; Stoyka L; Daher JP; Milnerwood AJ; Unni VK; Hirst WD; Yue Z; Zhao HT; Fraser K; Kennedy RE; West AB
J Neurosci; 2016 Jul; 36(28):7415-27. PubMed ID: 27413152
[TBL] [Abstract][Full Text] [Related]
57. Methods to Assess Oxidative DNA Base Damage Repair of Apurinic/Apyrimidinic (AP) Sites Using Radioactive and Nonradioactive Oligonucleotide-Based Assays.
Gupta KB; Kaur S; Dhiman M; Mantha AK
Methods Mol Biol; 2022; 2413():155-163. PubMed ID: 35044663
[TBL] [Abstract][Full Text] [Related]
58. Loss of tau expression attenuates neurodegeneration associated with α-synucleinopathy.
Vermilyea SC; Christensen A; Meints J; Singh B; Martell-Martínez H; Karim MR; Lee MK
Transl Neurodegener; 2022 Jul; 11(1):34. PubMed ID: 35773715
[TBL] [Abstract][Full Text] [Related]
59. Neurons and Glia Interplay in α-Synucleinopathies.
Mavroeidi P; Xilouri M
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066733
[TBL] [Abstract][Full Text] [Related]
60. Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein.
Howe JW; Sortwell CE; Duffy MF; Kemp CJ; Russell CP; Kubik M; Patel P; Luk KC; El-Agnaf OMA; Patterson JR
Parkinsonism Relat Disord; 2021 Aug; 89():41-47. PubMed ID: 34218047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
